We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Offers Guidance to Drugmakers on Immunotoxicity Studies
FDA Offers Guidance to Drugmakers on Immunotoxicity Studies
February 7, 2005
Manufacturers should begin nonclinical testing of all new investigational drugs to determine what, if any, impact they have on a patient's immune response, according to a new FDA draft guidance released under the auspices of the International Conference on Harmonisation.